Loading...
•
Jun 30, 2021
BeiGene Q2 2021 Earnings Report
BeiGene reported a strong second quarter in 2021, marked by significant revenue growth and progress in clinical development.
Key Takeaways
BeiGene reported a notable increase in product revenue, reaching $138.6 million in the second quarter of 2021, a 111% increase compared to the same period last year. The company saw growth in sales of BRUKINSA and tislelizumab, and continued advancements in its pipeline, including positive Phase 3 trial data and new regulatory approvals.
Product revenue increased by 111% year-over-year, reaching $138.6 million.
Positive interim Phase 3 BRUKINSA data reported from SEQUOIA and ALPINE trials.
Two Phase 3 clinical trials initiated for ociperlimab in NSCLC.
Plans announced to expand global manufacturing capabilities with a U.S. facility.
BeiGene
BeiGene
BeiGene Revenue by Segment
Revenue by Segment
Brukinsa Revenue
CapyFin.com Forward Guidance
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data for BeiGene’s drug candidates and approvals of its medicines; the conduct of late-stage clinical trials and expected data readouts; additional planned product approvals and launches; the advancement of and anticipated clinical development, regulatory milestones and commercialization of BeiGene’s medicines and drug candidates; the success of BeiGene’s commercialization efforts and revenue growth; the expected capacities and completion dates for the Company’s manufacturing facilities under construction; the timeline for the Company to complete its proposed public offering and listing on the STAR Market of the Shanghai Stock Exchange, if at all; the impact of the COVID-19 pandemic on the Company’s clinical development, regulatory, commercial and other operations; BeiGene’s plans and the expected events and milestones under the caption “Recent Business Highlights and Upcoming Milestones”; and BeiGene’s plans, commitments, aspirations and goals under the captions “About BeiGene”.
Positive Outlook
- Continued clinical evidence for the best-in-class potential of BRUKINSA.
- Expanded list of indications for tislelizumab in China.
- Progress with our differentiated Phase 3 stage, anti-TIGIT antibody, ociperlimab.
- Expansion of global manufacturing capabilities through establishment of a U.S. facility
- Listing of the Company’s ordinary shares on the STAR Market is expected to be completed in 2021, subject to market conditions and additional regulatory approvals
Challenges Ahead
- The Company expects that the worldwide health crisis of COVID-19 will continue to have a negative impact on its operations, including commercial sales, regulatory interactions, inspections, filings, and clinical trial recruitment, participation, and data read outs.
- BeiGene's ability to demonstrate the efficacy and safety of its drug candidates
- The clinical results for its drug candidates, which may not support further development or marketing approval
- Actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval
- BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved